The Tumor Microenvironment in Colorectal Carcinogenesis

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2011 Jan 7

PMID 21209781

Citations 112

Authors

Vijay G Peddareddigari

Dingzhi Wang

Raymond N DuBois

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Therapeutic developments in the past decade have extended life expectancy in patients with metastatic disease. However, metastatic colorectal cancers remain incurable. Numerous agents that were demonstrated to have significant antitumor activity in experimental models translated into disappointing results in extending patient survival. This has resulted in more attention being focused on the contribution of tumor microenvironment to the progression of a number of solid tumors including colorectal cancer. A more complete understanding of interactions between tumor epithelial cells and their stromal elements will enhance therapeutic options and improve clinical outcome. Here we will review the role of various stromal components in colorectal carcinogenesis and discuss the potential of targeting these components for the development of future therapeutic agents.

Citing Articles

Systemic immune profiling analysis identifying M2-TAM related genes predicted colon cancer prognosis and chemotherapy responses.

Liu X, Liu D, Tan C, Wang J Medicine (Baltimore). 2025; 103(52):e40979.

PMID: 39969348 PMC: 11688056. DOI: 10.1097/MD.0000000000040979.

Advanced diffusion-weighted imaging biomarkers for non-invasive assessment of tumor microenvironment in rectal cancer: restricted spectrum imaging.

Yuan J, Sun Y, Liu K, Han G, Wang Z, Liu M Abdom Radiol (NY). 2025; .

PMID: 39932551 DOI: 10.1007/s00261-025-04819-w.

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.

Integrating mechanism-based T cell phenotypes into a model of tumor-immune cell interactions.

Tangella N, Cess C, Ildefonso G, Finley S APL Bioeng. 2024; 8(3):036111.

PMID: 39175956 PMC: 11341129. DOI: 10.1063/5.0205996.

Both Th1 and Th2 CD4 + T-Cell Lineage Infiltrations Decrease in Post-hematopoietic Stem Cell Transplantation Colon Adenoma.

Matsubara Y, Ota Y, Denda T, Tanaka Y, Isobe M, Kato S J Gastrointest Cancer. 2024; 55(4):1551-1558.

PMID: 39158838 DOI: 10.1007/s12029-024-01097-5.

References

Illemann M, Bird N, Majeed A, Sehested M, Laerum O, Lund L . MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res. 2006; 4(5):293-302. DOI: 10.1158/1541-7786.MCR-06-0003. View

Linnekin D . Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999; 31(10):1053-74. DOI: 10.1016/s1357-2725(99)00078-3. View

Gupta R, DuBois R . Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2002; 1(1):11-21. DOI: 10.1038/35094017. View

Zins K, Abraham D, Sioud M, Aharinejad S . Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res. 2007; 67(3):1038-45. DOI: 10.1158/0008-5472.CAN-06-2295. View

Hallgren J, Estrada S, Karlson U, Alving K, Pejler G . Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry. 2001; 40(24):7342-9. DOI: 10.1021/bi001988c. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Kim S, Kim J, Papadopoulos J, Kim S, Maya M, Zhang F . Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol. 2009; 174(5):1972-80. PMC: 2671284. DOI: 10.2353/ajpath.2009.080819. View

Yaqub S, Henjum K, Mahic M, Jahnsen F, Aandahl E, Bjornbeth B . Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother. 2007; 57(6):813-21. PMC: 11030670. DOI: 10.1007/s00262-007-0417-x. View

Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmen C . Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005; 105(12):4642-8. DOI: 10.1182/blood-2004-08-3327. View

10.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

11.

Xu W, Schlagwein N, Roos A, van den Berg T, Daha M, van Kooten C . Human peritoneal macrophages show functional characteristics of M-CSF-driven anti-inflammatory type 2 macrophages. Eur J Immunol. 2007; 37(6):1594-9. DOI: 10.1002/eji.200737042. View

12.

Mizukami Y, Kohgo Y, Chung D . Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007; 13(19):5670-4. DOI: 10.1158/1078-0432.CCR-07-0111. View

13.

Baier P, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt U . Chemokines in human colorectal carcinoma. Anticancer Res. 2005; 25(5):3581-4. View

14.

Pockaj B, Basu G, Pathangey L, Gray R, Hernandez J, Gendler S . Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004; 11(3):328-39. DOI: 10.1245/aso.2004.05.027. View

15.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

16.

Waldner M, Schimanski C, Neurath M . Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol. 2006; 12(45):7233-8. PMC: 4087478. DOI: 10.3748/wjg.v12.i45.7233. View

17.

Finetti F, Donnini S, Giachetti A, Morbidelli L, Ziche M . Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway. Circ Res. 2009; 105(7):657-66. DOI: 10.1161/CIRCRESAHA.109.203760. View

18.

Zagani R, Hamzaoui N, Cacheux W, De Reynies A, Terris B, Chaussade S . Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. Gastroenterology. 2009; 137(4):1358-66.e1-3. DOI: 10.1053/j.gastro.2009.06.039. View

19.

Kopp H, Placke T, Salih H . Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009; 69(19):7775-83. DOI: 10.1158/0008-5472.CAN-09-2123. View

20.

Etoh T, Shibuta K, Barnard G, Kitano S, Mori M . Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res. 2000; 6(9):3545-51. View